COMPARISON OF DEFERASIROX AND DESFERRIOXAMINE AS IRON CHELATORS IN MULTI-TRANSFUSED PATIENTS OF Β-THALASSEMIA MAJOR

A AHMED; M KAMRAN; M MUKHTAR; M ALI; M UMAIR

doi:10.54112/bcsrj.v2023i1.270

Authors

A AHMED Department of Medicine, Mayo Hospital, Lahore, Pakistan
M KAMRAN Department of Medicine, Mayo Hospital, Lahore, Pakistan
M MUKHTAR Department of Pediatrics Medical Unit 1, Mayo Hospital Lahore, Pakistan
M ALI Department of Pediatrics Medical Unit 1, Mayo Hospital Lahore, Pakistan
M UMAIR Department of Internal Medicine, Mayo Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.270

Keywords:

Deferasirox, β-thalassemia, hematological

Abstract

This study aimed to compare the efficacy of deferasirox and deferoxamine in improving hematological and immunological parameters in patients with transfusion-dependent β-thalassemia major. 200 patients were enrolled in the study, with 100 receiving deferasirox and 100 receiving deferoxamine. The study was conducted at Mayo Hospital, Lahore. The patients were followed up for six months, during which various hematological and immunological parameters were measured at regular intervals. The data were analyzed using appropriate statistical methods. Both deferasirox and deferoxamine effectively improved hematological and immunological parameters in patients with β-thalassemia major. However, deferasirox was more effective than deferoxamine in improving hemoglobin, red blood cell count, and hematocrit levels. In contrast, there was no significant difference between the two iron chelators in their impact on white blood cell count and platelet count. Deferasirox appears to be a more effective iron chelator than deferoxamine in improving hematological parameters in patients with transfusion-dependent β-thalassemia major

Downloads

Download data is not yet available.

References

Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.

Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29(5):909-917.

Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017;92(5):420-428.

Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P. A phase II study of the efficacy, safety, and pharmacokinetics of oral once-daily deferiprone in patients with transfusion-dependent thalassemia. Blood. 2003;102(13):4199-4205.

Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica. 2006;91(10):1343-1351.

Al-Kuraishy HM, Al-Gareeb AI. Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia. Asian J Transfus Sci. 2017 Jan-Jun;11(1):13-17. doi: 10.4103/0973-6247.200768. PMID: 28316434; PMCID: PMC5345274.

Amah-Tariah FS, Ojeka SO, Dapper DV. Haematological values in pregnant women in Port Harcourt, Nigeria II: Serum iron and transferrin, total and unsaturated iron binding capacity and some red cell and platelet indices. Niger J Physiol Sci. 2011;26:173–8

Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y; CORDELIA study investigators. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 2014 Mar 6;123(10):1447-54. doi: 10.1182/blood-2013-04-497842. Epub 2014 Jan 2. PMID: 24385534; PMCID: PMC3945858.

Wood JC, Otto-Duessel M, Gonzalez I, Aguilar MI, Shimada H, Nick H, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res. 2006;148:272–80

Zhang XL, Pang W, Deng DY, Lv LB, Feng Y, Zheng YT. Analysis of immunoglobulin, complements and CRP levels in serum of captive Northern pig-tailed macaques (Macaca leonina) Dongwuxue Yanjiu. 2014;35:196–203.

Ghaffari J, Vahidshahi K, Kosaryan M, Soltantooyeh Z, Mohamadi M. Humoral immune system state in ß thalassemia major. Med Glas (Zenica) 2011;8:192–6.

Aleem A, Shakoor Z, Alsaleh K, Algahtani F, Iqbal Z, Al-Momen A. Immunological evaluation of ß-thalassemia major patients receiving oral iron chelator deferasirox. J Coll Physicians Surg Pak. 2014;24:467–71

Dan L, Anthony S, Dennis L, Stephen L, Jameson J, Joseph L. Harrison's Principles of Internal Medicine. 18th ed. New York: McG